Rho Chi Post

An award-winning, electronic, student-operated newsletter publication by the St. John's University College of Pharmacy and Health Sciences Rho Chi Beta Delta chapter

Menu

Skip to content
  • Home
  • Issues
    • Current Issue
    • All Issues
  • Articles
    • Featured
    • In the News / Politics
    • Events
    • Clinical
    • Advice / Opinions
    • Puzzles
    • Recently in PubMed
  • For Authors
    • Author Guidelines
    • AMA Citation Generator
    • Sign Up for Article(s)
    • Suggest Article(s)
    • Submit Article(s)
    • Check Statuses
    • Cite Your Article
  • About Us
    • About the Rho Chi Post
    • The Editorial Team
  • Apply for a Position
  • Subscribe
  • Login

Bamlanivimab for the treatment of COVID-19

By: Daniela Farzadfar, PharmD,PGY-1 Resident at Long Island Jewish Medical Center              In March 2020, the World Health Organization (WHO) declared coronavirus disease- 2019 (COVID-19) a global pandemic. 1 To date, over 30 million cases of COVID-19 have been reported in the United States and drug companies have been scrambling to develop therapies for the…

Continue reading →

Insulin Monitoring System for Pediatric patients

By: Lyana Sayilar, PharmD Candidate c/o 2022              On August 31, 2020, the FDA approved the first automated diabetes management device for patients aged 2 to 6-years old. The MiniMed 770G System automatically adjusts basal insulin doses based on glucose levels, facilitating the lives of the patient and caregiver. Prior to its approval, patients and/or…

Continue reading →

Who is COVID-19 hitting the hardest?

By: Pooja Dasgupta and Sonya Wadhawan, PharmD Candidates c/o 2025              The coronavirus, also known as SARS CoV-2 or COVID-19, has widely affected various people globally. The study of SARS CoV-2 has shifted from studying individuals and their unique symptoms during their disease duration to studying different populations and their backgrounds that increase the risk…

Continue reading →

The Cardiovascular Effects of Cannabis vs. Tobacco Consumption

By: Jeng Lee, PharmD Candidate c/o 2022               Throughout the past decade, there has been an increase in the prevalence of medical and recreational consumption of cannabis, also referred to as marijuana. 1 These numbers are expected to rise over the upcoming years in the United States as marijuana use is currently legalized in 33…

Continue reading →

New Drug Update: Lemborexant (Dayvigo ®)

By: Cindy Van, PharmD Candidate c/o 2022, Shireen Farzadeh, PharmD, BCPS              Insomnia is a condition characterized by difficulty falling asleep, staying asleep, or both, despite an adequate opportunity to sleep. Consequently, insomnia can lead to daytime fatigue, difficulty concentrating, and irritability. This condition can be categorized into short-term and chronic insomnia. While short-term insomnia…

Continue reading →

(Volume 10, Issue 4)
AstraZeneca Sells Rights to Two Cardiovascular Drugs for $400 Million

Bamlanivimab for the treatment of COVID-19

Emerging Type 3 Diabetes

Fostemsavir: New drug for the treatment of HIV-1 resistant patients

Increasing Evidence of the Benefits of Statins

Insulin Monitoring System for Pediatric patients

New Drug Update: Lemborexant (Dayvigo ®)

Rybelsus: Novel Oral GLP-1 Agonist and the Future of Oral Protein Dosage Forms

The Cardiovascular Effects of Cannabis vs. Tobacco Consumption

Who is COVID-19 hitting the hardest?

View Full Issue

Do You Want to be a Published Author? Submit your Article(s) Today!


 Tweets by @RhoChiPost
HOME: Home Page

VOLUMES / ISSUES: 10 . 9 . 8 . 7 . 6 . 5 . 4 . 3 . 2 . 1

ARTICLES: Featured . In the News / Politics . Events . Clinical . Advice / Opinions . Puzzles

FOR AUTHORS: Guidelines . AMA Citation Generator . Sign Up . Suggest . Submit . Cite

ABOUT US: About the Rho Chi Post . The Editorial Team . Apply for a Position

SUBSCRIBE: Google Groups Email List

Copyright © 2011-2021 Rho Chi Post